Company Encyclopedia
View More
name
Aclaris Therap
ACRS.US
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services.
4.514 T
ACRS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking140/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-113.23%E
    • Profit Margin-900.01%E
    • Gross Margin25.77%C
  • Growth ScoreE
    • Revenue YoY-41.87%E
    • Net Profit YoY-282.88%E
    • Total Assets YoY-3.76%D
    • Net Assets YoY-7.72%D
  • Cash ScoreD
    • Cash Flow Margin-11.11%D
    • OCF YoY-41.87%E
  • Operating ScoreE
    • Turnover0.09E
  • Debt ScoreB
    • Gearing Ratio31.58%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Aclaris Therapeutics: Promising Pipeline and Strategic Financial Management Justify Buy Rating

    Analyst Ram Selvaraju of H.C. Wainwright has reiterated a Buy rating on Aclaris Therapeutics, maintaining a price target of $16.00. This rating is supported by the company's promising pipeline, including the advancement of its anti-TSLP monoclonal antibody, bosakitug, into a Phase 2 trial for atopic dermatitis, and other key assets. Aclaris reported a net loss in Q3 2025 as expected but retains a strong cash position. Positive clinical results for ATI-2138 further bolster confidence in the company's growth prospects.

    Tip Ranks·
    US
    ACRS
    +8.27%
    Tip Ranks·
    US
    ACRS
    +8.27%

    Aclaris Therap | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 3.299 M

    LB filings·
    US
    ACRS
    +8.27%
    LB filings·
    US
    ACRS
    +8.27%

    Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows

    Aclaris Therapeutics reported Q3 revenue of $3.30 million, exceeding analyst expectations of $1.59 million, despite a year-over-year decline. The net loss narrowed to $14.6 million, better than the anticipated $15.8 million. The company announced positive Phase 2a trial results for ATI-2138 in atopic dermatitis and plans further trials in 2026. Analysts maintain a "buy" rating on the stock, with a 12-month price target of $7.00, reflecting a potential upside of 67.7% from its recent closing price of $2.26.

    Reuters·
    US
    ACRS
    +8.27%
    Reuters·
    US
    ACRS
    +8.27%

    Aclaris Therapeutics reports third quarter 2025 financial results

    Aclaris Therapeutics Inc. reported a decrease in cash reserves to $167.2 million as of September 30, 2025, down from $203.9 million at the end of 2024. The company experienced reduced revenue due to prior year milestones and licensing revenue. R&D expenses rose to $13.0 million for the quarter, driven by increased costs. Positive Phase 2a trial results for ATI-2138 were noted, with further trials expected in 2026. The company anticipates its cash will support operations into the second half of 2028.

    Reuters·
    US
    ACRS
    +8.27%
    Reuters·
    US
    ACRS
    +8.27%

    Aclaris Therap | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 3.299 M

    LB filings·
    US
    ACRS
    +8.27%
    LB filings·
    US
    ACRS
    +8.27%
    © 2025 Longbridge｜Disclaimer